Quintanal-Villalonga, Álvaro
Chan, Joseph M.
Yu, Helena A. http://orcid.org/0000-0002-0377-9510
Pe’er, Dana
Sawyers, Charles L. http://orcid.org/0000-0003-4955-6475
Sen, Triparna http://orcid.org/0000-0003-4673-7481
Rudin, Charles M. http://orcid.org/0000-0001-5204-3465
Article History
Accepted: 4 February 2020
First Online: 9 March 2020
Change Date: 17 March 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41571-020-0355-5
Competing interests
: H.A.Y. has been a consultant on oncology drug development for Astellas Pharma, Astra Zeneca, Daiichi, Lilly, Novartis and Pfizer, and is an inventor on a patent application for pulsatile use of erlotinib to treat or prevent metastases. C.L.S. serves on the board of directors of Novartis, is a co-founder of ORIC Pharmaceuticals and is a co-inventor of enzalutamide and apalutamide. He is a science adviser to Agios, Beigene, Blueprint, Column Group, Foghorn, Housey Pharma, Nextech, KSQ, Petra and PMV. C.M.R. has been a consultant on oncology drug development for AbbVie, Amgen, Ascentage, Astra Zeneca, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Genentech–Roche, Ipsen, Loxo, Pharmamar and Vavotek. He serves on the scientific advisory boards of Bridge Medicines and Harpoon Therapeutics. The other authors declare no competing interests.